MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy

E-ISSN： 1873-5576|5|1|27-41

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.5, Iss.1, 2005-02, pp. : 27-41

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical implications of chemotherapy-induced tumor gene expression in human breast cancers

By Tan Sing-Huang Lee Soo-Chin

Expert Opinion on Drug Metabolism and Toxicology, Vol. 6, Iss. 3, 2010-03 ,pp. : 283-306

Informa Healthcare

Access to resources Recommend Favorite

The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies

Current Pharmaceutical Design, Vol. 14, Iss. 21, 2008-07 ,pp. : 2100-2110

Bentham Science Publishers

Access to resources Recommend Favorite

Implications of systemic malignancies on human fertility

By Agarwal Ashok Said Tamer M

Reproductive BioMedicine Online, Vol. 9, Iss. 6, 2004-12 ,pp. : 673-679

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

MDM2 Splice Variants and Their Therapeutic Implications

Current Cancer Drug Targets, Vol. 5, Iss. 1, 2005-02 ,pp. : 21-26

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Surrogate Markers in the Clinical Evaluation of Antituberculous Chemotherapy

Current Medicinal Chemistry - Anti-Infective Agents, Vol. 4, Iss. 4, 2005-10 ,pp. : 287-294

Bentham Science Publishers

Access to resources Recommend Favorite